- Home
- FURY vs PRLD Comparison
FURY vs PRLD Comparison
Compare FURY & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- PRLD
- Stock Information
- Founded
- FURY 2008
- PRLD 2016
- Country
- FURY Canada
- PRLD United States
- Employees
- FURY N/A
- PRLD N/A
- Industry
- FURY Precious Metals
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- FURY Basic Materials
- PRLD Health Care
- Exchange
- FURY Nasdaq
- PRLD Nasdaq
- Market Cap
- FURY 84.1M
- PRLD 69.1M
- IPO Year
- FURY N/A
- PRLD 2020
- Fundamental
- Price
- FURY $0.55
- PRLD $1.30
- Analyst Decision
- FURY Strong Buy
- PRLD Strong Buy
- Analyst Count
- FURY 2
- PRLD 3
- Target Price
- FURY $1.40
- PRLD $4.00
- AVG Volume (30 Days)
- FURY 985.2K
- PRLD 3.3M
- Earning Date
- FURY 11-11-2025
- PRLD 10-31-2025
- Dividend Yield
- FURY N/A
- PRLD N/A
- EPS Growth
- FURY N/A
- PRLD N/A
- EPS
- FURY N/A
- PRLD N/A
- Revenue
- FURY N/A
- PRLD $7,000,000.00
- Revenue This Year
- FURY N/A
- PRLD N/A
- Revenue Next Year
- FURY N/A
- PRLD N/A
- P/E Ratio
- FURY N/A
- PRLD N/A
- Revenue Growth
- FURY N/A
- PRLD N/A
- 52 Week Low
- FURY $0.35
- PRLD $0.61
- 52 Week High
- FURY $0.89
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- FURY 38.83
- PRLD 47.35
- Support Level
- FURY $0.52
- PRLD $1.17
- Resistance Level
- FURY $0.60
- PRLD $4.19
- Average True Range (ATR)
- FURY 0.04
- PRLD 0.37
- MACD
- FURY -0.01
- PRLD -0.08
- Stochastic Oscillator
- FURY 17.24
- PRLD 4.69
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.